Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising.
Onco-Innovations (CBOE CA: ONCO)(OTCQB: ONNVF)(FSE: W1H) is advancing its lead preclinical cancer candidate, ONC010, toward potential first-in-human testing by bringing together drug manufacturing, nanoparticle formulation, analytical development, preclinical studies and regulatory planning. ONC010 combines the company’s PNKP-targeting small molecule A83B4C63 with a micellar nanoparticle delivery system intended to enhance drug exposure and tumor accumulation, with the broader strategy focused on disrupting cancer cells’ DNA repair mechanisms and potentially enhancing the effects of radiation and certain chemotherapy treatments. The company has completed a 300-gram development batch of A83B4C63 at approximately 99.3% purity, advanced polymer manufacturing and identified a non-tin catalyst that could improve impurity control, while also progressing pharmacokinetic, biodistribution, metabolism and ADME studies. With an Australian subsidiary established, clinical-development partners engaged and new scientific and clinical leadership in place, Onco is now working to integrate these activities into the manufacturing and regulatory package needed for a potential phase I/first-in-human study.
To view the full article, visit https://ibn.fm/whdu9
About Onco-Innovations Ltd.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. For more information, visit the company’s website at https://oncoinnovations.com/.
NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
